Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boundless BioBOLD -0.20%14 Debt-to-Equity is 0.56 as of Mar. 2026. GuruFocus rates BOLD with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 967 Biotechnology companies, Boundless Bio ranks worse than 77.87% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Boundless Bio's Debt-to-Equity or its related term are showing as below:
BOLD'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.06 Med: 0 Max: 0.56
Current: 0.56
During the past 5 years, the highest Debt-to-Equity Ratio of Boundless Bio was 0.56. The lowest was -0.06. And the median was 0.00.
BOLD's Debt-to-Equity is ranked worse than 77.87% of 967
companies
in the Biotechnology industry
Industry Median: 0.16
vs BOLD: 0.56
Boundless Bio (NAS:BOLD) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Boundless Bio Debt-to-Equity Related Terms
Boundless Bio Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Boundless Bio's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOLD vs INKT, FLNA, DWTX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Boundless Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boundless Bio Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Boundless Bio's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Boundless Bio's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boundless Bio (BOLD) has a Debt-to-Equity of 0.56 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Boundless Bio and its competitors. According to the industry distribution chart, Boundless Bio ranks #753 out of 967 companies in the Biotechnology industry, placing it in the top 77.9%.
Is Boundless Bio's Debt-to-Equity too high?
Boundless Bio's current Debt-to-Equity is 0.56. The Biotechnology industry median Debt-to-Equity is 0.16. Boundless Bio's value of 0.56 is 250% above this industry median. Based on the distribution chart, Boundless Bio ranks #753 out of 967 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Boundless Bio has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Boundless Bio's Debt-to-Equity compare to INKT and FLNA?
According to the Biotechnology industry distribution chart, Boundless Bio ranks #753 out of 967 companies for Debt-to-Equity. This places Boundless Bio in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Boundless Bio's value of 0.56 is 250% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boundless Bio's current Debt-to-Equity of 0.56 is 250% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Boundless Bio and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boundless Bio's current Debt-to-Equity is 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boundless Bio stock overvalued right now?
Boundless Bio (BOLD) has a current Debt-to-Equity of 0.56. The current Debt-to-Equity is 0.56 and 250% above the Biotechnology industry median of 0.16. Boundless Bio's overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Boundless Bio (BOLD), the current Debt-to-Equity is 0.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
14GF Score
Get the complete analysis for BOLD
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOLD has been successfully added to your 
